Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cosmax Nbt, Inc (222040) Fair Value & Analysis

Consumer Defensive · KR · Market cap 138B KRW

Price5,720 KRW
Fair Value10,649 KRW
Upside+86.2%
Quality93/100
Evidence: High Range 7,606 KRW – 14,793 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cosmax Nbt, Inc (222040) currently trades at 5,720 KRW, while our model-based Fair Value estimate is 10,649 KRW — implying the stock looks roughly 86.2% undervalued today. We read business quality at 93/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Cosmax Nbt, Inc. operates as a health functional food company in South Korea and internationally. It also provides original design and original brand manufacturing services. In addition, the company offers cosmetics, medicines, and medical supplies. It offers its products in tablets, capsules, liquid, and powder supplement form of dosages. The company serves its products through business to business, distribution companies, pharmaceutical and food companies, networks, and online channels. Cosmax Nbt, Inc. was founded in 2002 and is headquartered in Seongnam-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Cosmax Nbt, Inc (222040) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 10,649 KRW versus a price of 5,720 KRW — about +86% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 222040?
Our 21-model fair value for Cosmax Nbt, Inc is 10,649 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 5,720 KRW.
What is the quality score of 222040?
Cosmax Nbt, Inc has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.